Jazz Pharmaceuticals to Report Second Quarter Financial Results on August 5, 2025

Rhea-AI Summary

Jazz Pharmaceuticals (NASDAQ: JAZZ), a global biopharma company, has announced it will release its 2025 second quarter financial results on Tuesday, August 5, 2025, after U.S. market close. The company will host a live audio webcast at 4:30 p.m. EDT / 9:30 p.m. IST to discuss the results and provide business updates.

Participants are encouraged to register at least 15 minutes before the webcast through the company's website or direct registration link. A replay will be available in the Investors section of Jazz Pharmaceuticals' website. The company specializes in developing medicines for sleep disorders, epilepsy, and cancer treatments, with operations spanning multiple countries.

DUBLIN, July 22, 2025 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that it will report its 2025 second quarter financial results on Tuesday, August 5, 2025, after the close of the U.S. financial markets. Company management will host a live audio webcast at 4:30 p.m. EDT / 9:30 p.m. IST to discuss 2025 second quarter financial results and provide a business and financial update.

Interested parties may register for the call in advance here or via the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com. To ensure a timely connection, it is recommended that participants register at least 15 minutes prior to the scheduled webcast.

A replay of the webcast will be available via the Investors section of the Jazz Pharmaceuticals website at https://investor.jazzpharma.com/investors/events-presentations.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

Contacts:

Investors:
Jack Spinks
Senior Director, Investor Relations
Jazz Pharmaceuticals plc
InvestorInfo@jazzpharma.com
Ireland +353 1 634 3211
U.S. +1 650 496 2717

Media:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
CorporateAffairsMediaInfo@jazzpharma.com
Ireland +353 1 637 2141
U.S. +1 215 867 4948

View original content to download multimedia:https://www.prnewswire.com/news-releases/jazz-pharmaceuticals-to-report-second-quarter-financial-results-on-august-5-2025-302500657.html

SOURCE Jazz Pharmaceuticals plc

FAQ

When will Jazz Pharmaceuticals (JAZZ) report Q2 2025 earnings?

Jazz Pharmaceuticals will report its Q2 2025 earnings on Tuesday, August 5, 2025, after the U.S. financial markets close.

What time is Jazz Pharmaceuticals' Q2 2025 earnings call?

The earnings webcast will take place at 4:30 p.m. EDT / 9:30 p.m. IST on August 5, 2025.

How can investors access Jazz Pharmaceuticals' Q2 2025 earnings call?

Investors can register for the call through the direct registration link or via the Investors section at www.jazzpharmaceuticals.com. Registration should be completed 15 minutes before the webcast.

What are Jazz Pharmaceuticals' main business areas?

Jazz Pharmaceuticals focuses on developing medicines for sleep disorders, epilepsy, and cancer treatments, with a growing portfolio of innovative therapeutics in oncology and neuroscience.

Where can investors find the replay of Jazz Pharmaceuticals' Q2 2025 earnings call?

A replay of the webcast will be available in the Investors section of Jazz Pharmaceuticals' website at investor.jazzpharma.com/investors/events-presentations.